Atomoxetine and Executive Function in PTSD
NCT06573970
This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Attention deficits (AD) frequently co-occur with posttraumatic stress disorder (PTSD). The presence of AD is associated with greater PTSD clinical severity and poorer clinical outcomes. Knowledge regarding the mechanism underlying this association is limited, though the emerging evidence has indicated that executive function deficit (EFD) is strongly correlated with AD and PTSD symptoms. While treatments developed for PTSD have existed for years, a substantial portion of individuals do not fully respond to conventional treatment.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Posttraumatic Stress Disorder With Attention Defic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 4
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- VA Office of Research and Development
- Last updated on ClinicalTrials.gov
- July 7, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
South Carolina · 1
- Ralph H. Johnson VA Medical Center, Charleston, SC · Charleston, SC
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.